Opaleye Management Inc.
Q1 2014 13F-HR Holdings
Net value change ($000)
+7,986
(6.3%)
New positions
12
Sold out positions
4
Turnover %
67.1%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| TVTX | 24,448 | NEW |
| CHIMERIX INC | 12,242 | NEW |
| GenMark Diagnostics, Inc. | 4,324 | NEW |
| INSPIREMD INC | 3,611 | 122.4% |
| BIND THERAPEUTICS INC | 2,983 | 140.4% |
| Epizyme, Inc. | 2,630 | NEW |
| Flexion Therapeutics Inc | 2,229 | NEW |
| EVOK | 1,956 | NEW |
| CELGENE CORP RIGHT 12/31/2030 | 1,881 | NEW |
| ARIAD PHARMACEUTICALS INC | 1,603 | 13.5% |
Top Reduces (Value $000, Stocks/ETFs)
| GENTIUM SPA SPONSORED ADR | -29,240 | -100.0% |
| GERN | -10,901 | -82.6% |
| SUNSHINE HEART INC | -3,773 | -91.5% |
| INTERCEPT PHARMACEUTICALS, INC. | -3,642 | -100.0% |
| LGND | -2,506 | -51.6% |
| INFIQ | -1,671 | -100.0% |
| MEDIVATION | -1,600 | -100.0% |
| NPS PHARMACEUTICALS INC | -1,455 | -24.5% |
| PHARMACYCLICS INC | -1,435 | -11.1% |
| LAB | -1,069 | -21.2% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|